News from kinex pharmaceuticals, llc

Dec 03, 2012, 08:56 ET

PharmaEssentia Acquires Certain Asian Rights for Dermatology Preparations of Kinex Pharmaceuticals' Promising Novel Dual Src/Pretubulin Inhibitor, KX01

 Kinex Pharmaceuticals, LLC and PharmaEssentia Corporation announced today the execution of a licensing agreement granting PharmaEssentia...

Sep 10, 2012, 09:00 ET

Kinex Pharmaceuticals Appoints Mr. Patrick Gallagher Vice President of Business Development and Investor Relations

 Kinex Pharmaceuticals, LLC announced the appointment of Mr. Patrick (Pat) Gallagher to the position of Vice President, Business Development...

Jul 31, 2012, 08:45 ET

Kinex Pharmaceuticals Receives Substantial Strategic Investment

 Kinex Pharmaceuticals, LLC announced today that it has received a substantial investment from a prominent Asian investor. Dr. Manson Fok is...

Jun 05, 2012, 09:00 ET

Kinex Pharmaceuticals Appoints Dr. Jean-Pierre Sommadossi to the Board of Directors

 Kinex Pharmaceuticals, LLC announced today that Dr. David Hsia has elected to retire from the Board of Directors but will continue to...

Dec 19, 2011, 08:50 ET

Kinex Pharmaceuticals Acquires Rights for Technology and Products from Hanmi Pharmaceuticals, in United States and European Union Territories

Kinex Pharmaceuticals, LLC and Hanmi Pharmaceutical Co., Ltd. announced today the execution of a license agreement from Hanmi Pharmaceuticals...

May 17, 2011, 09:30 ET

The Board of Directors of Kinex Pharmaceuticals Appoints Dr. David Hangauer as Chief Scientific Officer

Kinex Pharmaceuticals, LLC announced today that Dr. David Hangauer, who served as the Founding Senior Vice President of Research, will be appointed...

May 09, 2011, 09:53 ET

The Board of Directors of Kinex Pharmaceuticals Appoints Dr. Allen Barnett as President Emeritus and Dr. Johnson Lau as Chief Executive Officer

Kinex Pharmaceuticals, LLC announced today that Dr. Allen Barnett, who served as the Founding Chief Executive Officer, has decided to step aside as...

Nov 27, 2007, 00:00 ET

First Patient Dosed with KX2-391 in Phase 1 Clinical Trial

BUFFALO, N.Y., Nov. 27 /PRNewswire/ -- Kinex Pharmaceuticals LLC, announced today that their drug KX2-391 (KX01) has begun Phase 1 human...

Jun 21, 2007, 01:00 ET

Kinex Pharmaceuticals Files Investigational New Drug Application for Novel Src Kinase Inhibitor, KX2-391

BUFFALO, N.Y., June 21 /PRNewswire/ -- Kinex Pharmaceuticals LLC, announced today that the Company has filed its first Investigational New Drug...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge